Christopher P. Molineaux - Jun 15, 2023 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role
Director
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol
ACRS
Transactions as of
Jun 15, 2023
Transactions value $
$338
Form type
4
Date filed
6/20/2023, 04:31 PM
Previous filing
Jun 5, 2023
Next filing
Jun 22, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRS Common Stock Options Exercise $36.70 +51 +0.16% $0.72* 31.8K Jun 15, 2023 Direct
transaction ACRS Common Stock Options Exercise $301 +198 +0.62% $1.52* 32K Jun 15, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRS Stock Option (right to buy) Options Exercise $0 -51 -100% $0.00* 0 Jun 15, 2023 Common Stock 51 $0.72 Direct F1
transaction ACRS Stock Option (right to buy) Options Exercise $0 -198 -100% $0.00* 0 Jun 15, 2023 Common Stock 198 $1.52 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares underlying this option vested on August 13, 2015 and the remaining shares vested in 36 equal monthly installments thereafter, subject to the reporting person's continued service with the Issuer as of the applicable vesting date.
F2 25% of the shares underlying this option vested on December 8, 2015 and the remaining shares vested in 36 equal monthly installments thereafter, subject to the reporting person's continued service with the Issuer as of the applicable vesting date.